Explain how a personalized mRNA vaccine trains tumor recognition

How Intismeran autogene (V940) works

Intismeran autogene (V940, also called mRNA-4157) is an investigational individualized neoantigen therapy. It encodes selected targets based on the mutational signature of a patient's tumor. This example follows the vaccine and the separate contribution of pembrolizumab in melanoma after surgery.

1. Select and encode. Tumor-specific changes inform the individualized mRNA design.
2. Deliver, translate and present. Antigen-containing proteins are produced and processed so peptides can be presented to the immune system.
3. Prime and recognize. Responsive T cells expand and can recognize matching peptide–MHC on a target cell.
4. Block an inhibitory interaction. Pembrolizumab binds PD-1 and blocks ligand engagement; this is distinct from the vaccine's antigen instructions.

The full 1-minute-56-second film has a light scientific score and English captions. The interactive experience includes the complete eight-stage journey and close molecular studies using experimental structures.

Eight stages from tumor sequence to immune response

A labeled mechanism figure connects individualized target selection, RNA delivery, translation, antigen presentation, T-cell priming, PD-1 blockade, recognition and a possible cellular response.

Recurrence-free survival after melanoma surgery

The clinical figure shows the KEYNOTE-942 Phase 2b recurrence-free survival hazard ratio with its confidence interval, and separately summarizes the Phase 3 INTerpath-001 topline.

The evidence brief identifies each study population, reported endpoint and source date. Numerical Phase 3 effect sizes were not disclosed in the cited August 2026 release; overall survival follow-up continues.

Scientific sources and representation limits

The mechanism summary below the film is based on the primary sources linked here. The source notes describe how those references relate to the visuals.

• KEYNOTE-942 five-year sponsor update, 20 January 2026
• INTerpath-001 Phase 3 topline, 19 August 2026
• Representative TCR–peptide–MHC structure, PDB 7PHR
• Human ribosome structure, PDB 8JDM
• Pembrolizumab Fab–PD-1 structure, PDB 5GGS
• Figure sources and representation notes

Intismeran remains investigational. The scene uses representative structural coordinates, not a measured V940 patient-specific recognition complex. Motion, cellular context and target-cell responses are illustrative. Clinical trial endpoints and reported effects are kept distinct from animated cell death. Pembrolizumab has serious immune-mediated risks; this example is not a complete safety presentation.

Apply the format to your program